Member Info for Cashintime

Back at IPO price once more. With so much achieved since then we should be at 15p minimum. We will see a POLB 001 deal at any time and this will propel us into a different level depending on terms. We have great prospects in a carefully selected product line. Nasdaq listing will see us at a multi hundred million market cap and will give us a greater liquidity on our stock. Plenty going on in the background in this fast moving pace company. We have a great team built up throughout last year that will bear fruit in 2023.

Another 500000+ buy @ 9.9p. premium to buy quantity.

Thanks that explains that so. Things looking up here,follow the money.

Google share showing 10p, was there a late trade@17.15. It's not showing up or is it just a glitch

I wonder if February will be the month here. I am in Aminex so long now it would be nice to get a chance to break even. I remember when we though and rightfully so that our farm out would give us a couple of hundred million. I got burned with Scirocco. That wind of change got me. What a joke they are and what a sponging crew running that company. They promised so much. That gas deal could have been mega. That's AIM for you. Let us see will the Zubairs try something tricky here.

No news until April was never pointed out in any RNS. They can drop at any time. You have to be in to win
It doesn't always work out but those stakeholders here consider it to be a safe bet. Are you a holder yourself.

It shows what has to be paid if anybody want any quantity. News is never too far away with Poolbeg, practically weekly. Hope the RNSs this year will be bagger makers.

It is encouraging that we are holding the price. I think the market is getting an understanding that we are spun from a now proven stable with Hvivo excellent results and the recent 1.4B deal for Amyrt. There is many leading professionals lending their good name to Poolbeg. It has a top class range of products which will be proven up this year. Collaborations will be made at any time from now and will lead to a good rerate here. We will be in Nasdaq this time next year if all goes to plan and will have a market capitalisation in the 100s of millions. We are not hanging about with our progressive work model, meeting all timelines as we go. AI results will put us in a different league as we are staying ahead of the industry curve and are near pioneers in what we are doing with our unique data here.
A play for the company could be possible if we hit the radar of interest from big Pharma,who knows.

Great day here, I had a little top slice here,not quiet entering free carry territory but not far off it. This is a great company which has a fantastic model and has become the world leader in human challenge studys. My main holding is Poolbeg Pharma now as I was late to the table here.

Some Hvivo profits should come over to Poolbeg later. News should be soon with new RSV candidates identified by the One Three collaboration. We should hear more patent news from America soon also as the stated previously that the claim would be allowable for Polb 001. Full IP on its way. At any time big news could break concerning partnerships for any of our growing products. We are a fast moving company with a great management team that aint sitting on their laurels. We have been getting new news at least weekly.

Great results over there. Our time will come here. Those results will quieten the naysayers a bit. There is no hiding from a good performance like that.

https://youtu.be/-vFuj02k2EI

Prof Brendan Buckley talks throught POLB 001 use with Car T.
Also race for Billion dollar plus RSV vaccine.

https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.investors.com/news/technology/4-pharmaceutical-stocks-are-close-to-cracking-multibillion-dollar-rsv-vaccine-market/&ved=2ahUKEwjsyMjQ-dj8AhWCaMAKHZ84DMkQ0PADKAB6BAgeEAE&usg=AOvVaw14JQFOqkrLl82rOr7l5hji

The traders must be all gone here for the moment. The board is gone very quiet. MMs will have to raise the bid if they want to churn a few trades.

AI gathering momentum in 2013, with a mention of Poolbeg finding new RSV target using technology. They will be getting their patents and IP rights ready pre announcing their findings from recent One Three collaboration.

https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.pharmaceutical-technology.com/comment/ai-momentum-biopharmaceutical/&ved=2ahUKEwiz362OytT8AhWQP8AKHY9dAvcQxfQBKAB6BAgJEAI&usg=AOvVaw1MufN5Ogvqb5p1DwTco2yR

That is a big trade. We would have to get a TR1 to know what is happening there. Maybe the big institutions taking a stake.

https://youtu.be/jSyFzAZj7BE

Last night's presentation for anybody who missed it.

There is no doubt that POLB 001 is still our flagship product. It has shown in preliminary results of the LPS human trial to be a working inhibitor as a blocker of P38. Now will oncology use added to the stable it has given it an increased value and opertuinity to partner. With IP rights already sorted, more patents filed and full data to come in the next quarter the future is bright here in Poolbeg. If we can attract investors who believe in the model it will give us a good lift in shareprice.

At least we are back at IPO price.
We do deserve to be at higher market cap after so much achieved in

Above IPO once more, can we plough on through it and hold, let's see.